#United States #New York #Class Action #Pacira BioSciences #PCRX

Attention Pacira BioSciences, Inc. Investors

The Gross Law Firm has recently issued an important reminder for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) concerning an impending class action lawsuit. Shareholders who acquired shares during a specified class period are urged to take swift action to protect their rights and potential recoveries.

Important Class Period and Allegations

The relevant class action relates to shares purchased between August 2, 2023, and August 8, 2024. The allegations stated in the complaint center around a significant court ruling that impacted the validity of a key patent held by Pacira. On August 9, 2024, Pacira publicly announced the results of their legal battle against eVenus concerning patent infringement, disclosing that the court had invalidated their U.S. Patent No. 11,033,495—which pertains to Exparel. This product is vital to Pacira’s revenue generation, constituting approximately 80% of the company's earnings.

With the invalidation of the '495 patent, financial analysts are now questioning the legitimacy of Pacira’s other patents, raising concerns about possible generic competition entering the market and the specter of future litigation costs. Following this bombshell announcement, Pacira’s stock price saw a staggering decrease—from a closing price of $22.36 on August 8, 2024, to a low of $11.70 on August 9, marking a disastrous drop of over 47% in just one day.

Registration and Next Steps for Shareholders

The deadline for shareholders to register for lead plaintiff status in this lawsuit is scheduled for March 14, 2025. It is crucial for investors who believe they have incurred losses from the stock's dramatic plunge to enlist in this class action to seek a potential refund. Unfortunately, many investors remain unaware of such legal avenues that can provide a measure of recovery from financial losses.

Those wishing to partake in this class action suit can register by following this link. After registering, shareholders will gain access to portfolio monitoring services that will keep them informed about the developments in this case.

The Role of the Gross Law Firm

The Gross Law Firm is a nationally recognized entity specializing in class action lawsuits, committed to protecting the rights of investors who have suffered losses caused by deceptive or unlawful practices. With a strong focus on upholding corporate responsibility, the firm strives to recover losses for those adversely impacted by misleading statements or omitted vital information that inflated stock values artificially.

If you are a shareholder of Pacira BioSciences, Inc. and want more information, don’t hesitate to reach out to The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This notice serves not only as a reminder of the pressing deadline but also as an alert to the financial risks associated with corporate secrets and patent lawsuits. Investors are advised to stay informed and act promptly to secure their interests in these turbulent times in the investment landscape.